Walgreens Faces DOJ Lawsuit Over Alleged Role in Opioid Crisis

The opioid crisis has left scars on communities across America, claiming hundreds of thousands of lives over the past two decades. While pharmaceutical manufacturers and rogue prescribers often dominate the headlines, pharmacy chains have increasingly found themselves in the DOJ’s crosshairs for their alleged role in this public health disaster. Now, Walgreens Boots Alliance, one of the nation’s largest pharmacy chains, faces a civil lawsuit from the Justice Department for allegedly fueling the epidemic by dispensing millions of unlawful prescriptions.

The lawsuit, filed in the Northern District of Illinois, accuses Walgreens of violating the Controlled Substances Act (CSA) and the False Claims Act (FCA). It paints a damning picture of systemic failures, alleging that Walgreens pharmacists routinely ignored glaring red flags to fill illegitimate prescriptions for opioids and other controlled substances, sometimes with tragic consequences.

Red Flags, Ignored

The DOJ’s complaint spans more than a decade, from August 2012 to the present. During this period, Walgreens allegedly filled prescriptions for excessive quantities of opioids, early refills, and the notorious "trinity" cocktail—a dangerous combination of an opioid, a benzodiazepine, and a muscle relaxant. According to the lawsuit, these prescriptions were filled despite clear indications of fraud or abuse.

The allegations suggest that Walgreens’ corporate culture played a significant role in perpetuating these practices. Pharmacists, the complaint says, were pressured to prioritize speed and volume over due diligence, leaving little room to verify whether prescriptions were legitimate. Worse, Walgreens allegedly prevented pharmacists from sharing crucial information about suspicious prescribers, creating a siloed system that allowed unlawful prescriptions to flow unchecked.

Principal Deputy Assistant Attorney General Brian M. Boynton didn’t mince words: “Our complaint alleges that Walgreens systematically pressured its pharmacists to fill prescriptions…without taking the time needed to confirm their validity. These practices allowed millions of opioid pills and other controlled substances to flow illegally out of Walgreens stores.”

A Familiar Pattern of Corporate Negligence

The recent tidal wave of enforcement actions against prominent financial institutions and corporations signals a crucial turning point in the global fight against unethical practices. Regulatory bodies, armed with sharper tools and broader mandates, are sending a clear message: no organization is beyond accountability. Amid these developments, McKinsey & Company's $650 million settlement for its role in the opioid epidemic stands as a sobering benchmark of corporate malfeasance—a warning to industries navigating the murky waters of profit-driven decision-making.

Few cases encapsulate the catastrophic consequences of unchecked corporate influence better than McKinsey’s role in the opioid epidemic. The consulting giant’s decade-long advisory services to Purdue Pharma weren’t just a footnote in the crisis—they were a driving force behind the aggressive marketing of OxyContin. Strategies like the “Evolve to Excellence” campaign, which targeted “High Value Prescribers,” epitomize the dangerous alchemy of data and profit-focused intent.

As a result of these strategies, McKinsey didn’t merely aid Purdue in boosting sales; it helped fuel a public health catastrophe that has claimed over 727,000 lives since 1999. The numbers are staggering, but they fail to capture the individual tragedies—the lives lost, families shattered, and communities ravaged by addiction.

The Department of Justice’s settlement with McKinsey, including $324 million in criminal fines and a five-year Deferred Prosecution Agreement (DPA), underscores the high stakes of consulting without accountability. Yet for many, the penalties feel hollow in the face of such irreparable harm.

The McKinsey case was followed by the DOJ’s action against CVS Pharmacy. Like Walgreens, CVS stands accused of knowingly dispensing unlawful prescriptions and prioritizing profits over patient safety. Both cases share a troubling narrative of pharmacies turning a blind eye to suspicious activities, enabling the opioid crisis to spiral further out of control.

In the CVS lawsuit, the DOJ highlighted corporate policies that left pharmacists overwhelmed and under-resourced, echoing allegations against Walgreens. In both cases, the DOJ has sought not only financial penalties but systemic reforms aimed at breaking the cycle of negligence that has plagued the pharmacy sector.

The Human Toll

Beyond the legal arguments and corporate posturing, the human cost of these failures is staggering. According to the complaint, some patients died of overdoses shortly after filling unlawful prescriptions at Walgreens. These tragic outcomes underscore the critical role pharmacies play as gatekeepers in the fight against opioid abuse.

“Pharmacies are the last line of defense in preventing dangerous drugs from reaching the wrong hands,” said DEA Principal Deputy Administrator George Papadopoulos. “Walgreens placed the public in danger by disregarding their responsibility.”

The DOJ’s actions also underscore the growing enforcement focus on pharmacies and other players in the opioid supply chain. Financial penalties, while substantial, are only part of the equation. Injunctive relief measures—such as stricter compliance requirements and closer regulatory scrutiny—are increasingly part of the DOJ’s toolkit to prevent future misconduct.

If found liable, Walgreens could face civil penalties of up to $80,850 for each unlawful prescription filled in violation of the CSA, as well as treble damages and penalties under the FCA. Given the scale of the alleged misconduct, the financial and reputational fallout could be enormous.

Yet, as the DOJ’s crackdown intensifies, it is clear that the era of unchecked corporate negligence in the pharmacy sector is coming to an end. For Walgreens, CVS, and others in the industry, the message is unequivocal—compliance is not optional, and the stakes couldn’t be higher.

The GRC Report is your premier destination for the latest in governance, risk, and compliance news. As your reliable source for comprehensive coverage, we ensure you stay informed and ready to navigate the dynamic landscape of GRC. Beyond being a news source, the GRC Report represents a thriving community of professionals who, like you, are dedicated to GRC excellence. Explore our insightful articles and breaking news, and actively participate in the conversation to enhance your GRC journey.